Athira Pharma, Inc. Stock News

Industry Veteran Brings More than 20 Years of Experience in CNS Drug Development and Commercialization Industry Veteran Brings More than 20 Years of Experience in CNS Drug Development and Commercializ

BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal heal

BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health

BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal healt

BOTHELL, Wash., March 17, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced it will report financial results for the fourth quarter and full year ended December 31, 2021 and provide a business update on Thursday, March 24, 2022 following the close of the U.S. financial markets. Athira will host a conference call to discuss these results on Thursday, March 24, 2022 at 4:30 pm Eastern time (1:30 pm Pacific time).

BOTHELL, Wash., March 14, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal healt

BOTHELL, Wash., March 14, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA ), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that an overview and update of the fully enrolled ACT-AD Phase 2 clinical trial with Athira''s lead development candidate fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer''s disease, will be presented at the International Conference on Alzheimer''s & Parkinson Diseases™ 2022, AD/PD™ 2022 hybrid​ congress, taking place March 15-20, 2022 virtually and in Barcelona. Presentation Details: Title: Study Design and Participant Characteristics of a Phase 2 trial of ATH-1017, a Novel Treatment for Mild-to-Moderate Alzheimer''s Disease Session: Abeta and other targeting therapies in AD (#113) Presenter: Hans Moebius, M.D., Ph.D., Chief Medical Officer, Athira Pharma, Inc. Date and Time: Sunday, March 20, 2022, 9:50 a.m. CET Location: Barcelona, Spain The presentation slides and an accompanying poster will be available on the Events and Presentations page of the Investors section of Athira''s website at www.athira.com .

BOTHELL, Wash., March 14, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health

Active metabolite of fosgonimeton (ATH-1017) enhances the HGF/MET system, resulting in neurotrophic and procognitive effects

Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models

Fosgonimeton demonstrated a statistically significant improvement of Event-Related Potential (ERP) P300 latency as compared with placebo in Alzheimer''s disease patients Fosgonimeton was well-tolerated across all dose levels and showed dose-proportional pharmacokinetics and encouraging pharmacodynamic activity Announces fosgonimeton as World Health Organization''s recommended international nonproprietary name for ATH-1017 BOTHELL, Wash., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA ), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the peer-reviewed publication of data from a Phase 1 clinical trial of fosgonimeton (ATH-1017) in The Journal of Alzheimer''s Disease . The article, titled "Safety, tolerability, pharmacokinetics and pharmacodynamics of the positive modulator of HGF/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer''s disease: randomized, placebo-controlled, double-blind, Phase 1 clinical trial," and includes results demonstrating that fosgonimeton showed a positive safety and tolerability profile across all dose levels tested and dose-proportional pharmacokinetics and encouraging pharmacodynamic activity. "These encouraging results showed a positive safety and tolerability profile of fosgonimeton across a wide dose range, and the pharmacodynamics support blood brain barrier penetration.

Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models

BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health

BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal healt

BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA ), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in SHAPE, a Phase 2 clinical trial of ATH-1017 for the treatment of Parkinson''s disease dementia and Dementia with Lewy bodies. ATH-1017 is a small molecule designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue. "The initiation of SHAPE is an important milestone in the advancement of our clinical development of ATH-1017. This small molecule is designed to impact neurodegeneration by focusing on network recovery and information transmission in the brain," said Hans Moebius, M.D., Ph.D., Chief Medical Officer at Athira. "SHAPE incorporates key endpoints to measure cognition, function and behavior, as well as including exploratory endpoints for motor function.